Opportunity Information: Apply for RFA AT 19 011
The funding opportunity titled "HEAL Initiative: Limited Competition: Resource Coordinating Center for Pragmatic and Implementation Studies for the Management of Pain (PRISM) to Reduce Opioid Prescribing (U24 Clinical Trial Not Allowed)" (Funding Opportunity Number RFA-AT-19-011) is a National Institutes of Health (NIH) cooperative agreement aimed at maintaining and expanding a central coordinating function that supports large, real-world research efforts in healthcare systems. It sits within the NIH HEAL Initiative framework, reflecting a broader federal push to address the opioid crisis by improving pain management practices and reducing unnecessary or high-risk opioid prescribing through evidence-based, system-level change.
At its core, this announcement solicits applications to continue an existing Coordinating Center that provides national leadership for the NIH Health Care Systems (HCS) Research Collaboratory program. The HCS Research Collaboratory is designed to make pragmatic research easier to plan, launch, and run in routine care settings such as health systems and large clinical networks, where studies must work within operational constraints, electronic health record environments, and complex clinical workflows. The opportunity specifically expands the Coordinating Center's responsibilities to also include oversight and coordination of trials funded under the PRISM initiative, which focuses on pragmatic and implementation studies for pain management strategies that can reduce opioid prescribing. In practical terms, NIH is looking for a hub that can help multiple funded projects align around consistent methods, shared resources, and coordinated problem-solving, rather than having each study reinvent infrastructure and procedures on its own.
The funding instrument is a cooperative agreement (U24), which signals that NIH expects substantial involvement from program staff in the conduct and stewardship of the overall program. Cooperative agreements typically require close coordination, shared governance expectations, and active engagement with NIH on priorities, milestones, and program-wide integration. The FOA is explicitly designated as "Clinical Trial Not Allowed," meaning the Coordinating Center itself is not expected to propose or run an independent clinical trial under this award mechanism. Instead, the Center's role is supportive and coordinating: enabling, harmonizing, advising, and providing shared services and expertise to the broader set of pragmatic and implementation studies funded elsewhere, including those under PRISM.
This announcement is described as a limited competition, which generally indicates that eligibility may be restricted to a narrow set of applicants, often tied to existing awardees or specific prior participation. While the summarized source data lists eligible applicants as public and state-controlled institutions of higher education, the full FOA language typically provides the definitive eligibility rules and any limitations related to the "limited competition" status. The announcement also places clear restrictions on foreign involvement: non-domestic (non-U.S.) entities (foreign institutions) are not eligible to apply, non-domestic components of U.S. organizations are not eligible, and foreign components as defined by the NIH Grants Policy Statement are not allowed. In effect, the work supported by this award must be carried out entirely within allowable U.S.-based organizational structures, without foreign components.
From a programmatic standpoint, the Coordinating Center is meant to function as a national resource that strengthens the design and execution of pragmatic and implementation research in healthcare delivery settings, with an emphasis on pain care and opioid prescribing reduction. This typically involves developing and disseminating best practices, providing technical assistance, supporting common data and outcome approaches where appropriate, facilitating collaboration across studies, and helping ensure that research can be implemented in operational clinical environments. Because PRISM studies are expected to be conducted in real-world healthcare systems, coordination becomes especially important for topics like stakeholder engagement, workflow integration, ethics and regulatory considerations in pragmatic research, data quality and extraction from electronic health records, and consistent approaches to implementation and evaluation.
Key administrative details from the source information include: the sponsoring agency is NIH; the opportunity category is discretionary; the activity category is health; the CFDA number is 93.213; the FOA was created on 2019-04-26; and the original application closing date was 2019-07-08. The provided source extract does not specify an award ceiling or the number of expected awards, suggesting those fields were either not populated in the extract or were defined only in the full announcement text. As with most NIH announcements, the FOA itself would be the controlling document for details such as budget expectations, project period, required components of the application, review criteria, and any mandatory participation in governance structures or steering committees.
Overall, this opportunity is best understood as NIH investing in shared national infrastructure and leadership to accelerate high-quality, real-world research on pain management and opioid prescribing practices. Rather than funding a single study, it funds the connective tissue that helps multiple studies run more efficiently, consistently, and credibly across diverse healthcare systems, with the ultimate aim of producing evidence and implementation strategies that can be adopted at scale to improve pain care and reduce opioid-related harms.Apply for RFA AT 19 011
- The National Institutes of Health in the health sector is offering a public funding opportunity titled ""HEAL Initiative: Limited Competition: Resource Coordinating Center for Pragmatic and Implementation Studies for the Management of Pain (PRISM) to Reduce Opioid Prescribing (U24 Clinical Trial Not Allowed)"" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.213.
- This funding opportunity was created on 2019-04-26.
- Applicants must submit their applications by 2019-07-08. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Public and State controlled institutions of higher education.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the official title of this funding opportunity?
The funding opportunity is titled "HEAL Initiative: Limited Competition: Resource Coordinating Center for Pragmatic and Implementation Studies for the Management of Pain (PRISM) to Reduce Opioid Prescribing (U24 Clinical Trial Not Allowed)."
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is RFA-AT-19-011.
Who is the sponsoring agency?
The sponsoring agency is the National Institutes of Health (NIH).
What broader federal effort does this opportunity align with?
This opportunity sits within the NIH HEAL Initiative, which reflects a broader federal push to address the opioid crisis by improving pain management practices and reducing unnecessary or high-risk opioid prescribing through evidence-based, system-level change.
What type of award is this?
This is a cooperative agreement (U24).
What does it mean that this is a cooperative agreement (U24)?
A cooperative agreement indicates NIH expects substantial involvement from NIH program staff in the conduct and stewardship of the overall program. This typically involves close coordination, shared governance expectations, and active engagement with NIH on priorities, milestones, and program-wide integration.
Is a clinical trial allowed under this award?
No. The opportunity is explicitly designated as "Clinical Trial Not Allowed," meaning the Coordinating Center itself is not expected to propose or run an independent clinical trial under this award mechanism.
If the Coordinating Center cannot run a clinical trial, what is it expected to do?
The Center is expected to play a supportive, coordinating role across other funded pragmatic and implementation studies. This includes enabling and harmonizing work across projects, advising, and providing shared services and expertise so that individual studies do not need to recreate infrastructure and procedures independently.
What is the main purpose of the award?
The main purpose is to maintain and expand a central coordinating function that supports large, real-world research efforts in healthcare systems, with a particular emphasis on pain management strategies that can reduce opioid prescribing.
What specific coordinating function is NIH seeking to continue?
NIH is soliciting applications to continue an existing Coordinating Center that provides national leadership for the NIH Health Care Systems (HCS) Research Collaboratory program.
What is the NIH Health Care Systems (HCS) Research Collaboratory?
The HCS Research Collaboratory is designed to make pragmatic research easier to plan, launch, and run in routine care settings such as health systems and large clinical networks, where studies must operate within real-world constraints, electronic health record environments, and complex clinical workflows.
How does PRISM relate to the Coordinating Center responsibilities?
This opportunity expands the Coordinating Center's responsibilities to include oversight and coordination of trials funded under the PRISM initiative, which focuses on pragmatic and implementation studies for pain management strategies intended to reduce opioid prescribing.
What does PRISM stand for in this context?
PRISM refers to Pragmatic and Implementation Studies for the Management of Pain to Reduce Opioid Prescribing.
What is meant by "pragmatic and implementation studies" in the context provided?
Based on the description, these are real-world studies conducted in routine healthcare delivery settings, designed to fit within operational clinical environments and evaluate approaches that can be implemented at scale. The opportunity emphasizes system-level change and evidence-based strategies that can reduce opioid prescribing while improving pain care.
Why does NIH want a single hub or coordinating center instead of having each project operate independently?
NIH is looking for a central hub to help multiple funded projects align around consistent methods, shared resources, and coordinated problem-solving. This approach reduces duplication and helps studies avoid "reinventing" infrastructure and procedures on their own.
What kinds of settings are these studies expected to take place in?
The supported program focuses on research in routine care settings such as healthcare systems and large clinical networks, where studies must work within operational constraints, electronic health record environments, and complex workflows.
What kinds of activities might the Coordinating Center support (as described in the summary)?
The summary describes a Coordinating Center that functions as a national resource by strengthening design and execution of pragmatic and implementation research. Typical activities include developing and disseminating best practices, providing technical assistance, supporting common data and outcome approaches where appropriate, facilitating collaboration across studies, and helping ensure research can be implemented in operational clinical environments.
What cross-study coordination topics are highlighted as especially important?
The summary highlights coordination needs in areas such as stakeholder engagement, workflow integration, ethics and regulatory considerations in pragmatic research, data quality and extraction from electronic health records, and consistent approaches to implementation and evaluation.
What does "limited competition" mean for applicants?
The opportunity is described as a limited competition, which generally indicates eligibility may be restricted to a narrow set of applicants, often tied to existing awardees or specific prior participation. The definitive eligibility rules and any limitations would be in the full FOA language.
Which applicants are listed as eligible in the provided summary?
The summarized source data lists eligible applicants as public and state-controlled institutions of higher education.
Are non-U.S. (foreign) organizations eligible to apply?
No. Non-domestic (non-U.S.) entities (foreign institutions) are not eligible to apply.
Can a U.S. organization include a non-U.S. component under this award?
No. The summary states that non-domestic components of U.S. organizations are not eligible.
Are foreign components allowed under NIH policy for this opportunity?
No. The summary specifies that foreign components, as defined by the NIH Grants Policy Statement, are not allowed.
What is the practical impact of the foreign eligibility restrictions?
Based on the summary, the work supported by this award must be carried out entirely within allowable U.S.-based organizational structures, without foreign components.
What is the opportunity category and activity category?
The opportunity category is discretionary, and the activity category is health.
What is the CFDA number for this opportunity?
The CFDA number listed is 93.213.
When was this FOA created and when was the original application closing date?
The FOA was created on 2019-04-26, and the original application closing date was 2019-07-08.
Does the provided summary include the award ceiling or expected number of awards?
No. The provided source extract does not specify an award ceiling or the number of expected awards, suggesting those fields were not populated in the extract or were only defined in the full announcement text.
Where should applicants look for definitive requirements like budget expectations, project period, and review criteria?
The full FOA is the controlling document for details such as budget expectations, project period, required components of the application, review criteria, and any mandatory participation in governance structures or steering committees.
In plain terms, what is NIH funding here: a research study or infrastructure?
This opportunity is best understood as funding shared national infrastructure and leadership: the "connective tissue" that helps multiple pragmatic and implementation studies run more efficiently, consistently, and credibly across diverse healthcare systems, with the ultimate aim of producing evidence and implementation strategies that can be adopted at scale to improve pain care and reduce opioid-related harms.
Browse more opportunities from the same category: Health
Next opportunity: The Pastoral Areas Resilience Activity (PARA)
Previous opportunity: Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AT 19 011
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AT 19 011) also looked into and applied for these:
| Funding Opportunity |
|---|
| HIV/AIDS Clinical Trials Units (UM1 Clinical Trial Required) Apply for RFA AI 19 045 Funding Number: RFA AI 19 045 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| HLA and KIR Region Genomics in Immune-Mediated Diseases (U19 Clinical Trial Not Allowed) Apply for RFA AI 19 044 Funding Number: RFA AI 19 044 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models (R41/R42 Clinical Trial Not Allowed) Apply for PAR 19 266 Funding Number: PAR 19 266 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models (R43/R44 Clinical Trial Not Allowed) Apply for PAR 19 265 Funding Number: PAR 19 265 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Conference for Early Stage HIV/AIDS Researchers Using Nonhuman Primate Models (R13 Clinical Trial Not Allowed) Apply for PAR 19 268 Funding Number: PAR 19 268 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Medicare Model Guidelines, Version 8 Apply for CMS 1C0 19 001 Funding Number: CMS 1C0 19 001 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: $100,000 |
| HIV/AIDS Scholars Using Nonhuman Primate (NHP) Models Program (K01 Independent Clinical Trial Not Allowed) Apply for PAR 19 267 Funding Number: PAR 19 267 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Lucidity in Dementia (R21/R33 Clinical Trial Optional) Apply for RFA AG 20 017 Funding Number: RFA AG 20 017 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Lucidity in Dementia (R21 Clinical Trial Optional) Apply for RFA AG 20 016 Funding Number: RFA AG 20 016 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Cognitive Systems Analysis of Alzheimer's Disease Genetic and Phenotypic Data (U01 Clinical Trial Not Allowed) Apply for PAR 19 269 Funding Number: PAR 19 269 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| The NIGMS Human Genetic Cell Repository (U42 - Clinical Trial Not Allowed) Apply for RFA GM 19 002 Funding Number: RFA GM 19 002 Agency: National Institutes of Health Category: Health Funding Amount: $2,000,000 |
| Summer Research Training in Aging for Medical Students (T35 Clinical Trial Not Allowed) Apply for RFA AG 20 008 Funding Number: RFA AG 20 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Pragmatic Trials of Managing Multimorbidity in Alzheimer's Disease (R61/R33 Clinical Trial Required) Apply for RFA AG 20 029 Funding Number: RFA AG 20 029 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Centers Without Walls for Collaborative Research in the Epilepsies: Functional Evaluation of Human Genetic Variants (U54 Clinical Trial Not Allowed) Apply for RFA NS 19 019 Funding Number: RFA NS 19 019 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
| Private Sector Partnership Addressing Emerging Zoonoses and Antimicrobial Resistance Apply for GH BAA 2018 ADDENDUM02 Funding Number: GH BAA 2018 ADDENDUM02 Agency: Agency for International Development Category: Health Funding Amount: $40,000,000 |
| NIAID Clinical Trial Planning Grant (R34 Clinical Trial Not Allowed) Apply for PAR 19 281 Funding Number: PAR 19 281 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| Sponsored Programs Administration Development (SPAD) Program (UC2 - Clinical Trial Not Allowed) Apply for RFA RM 19 004 Funding Number: RFA RM 19 004 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Innovations in Malaria Vaccine Development (IMV) Apply for GH BAA 2018 ADDENDUM03 Funding Number: GH BAA 2018 ADDENDUM03 Agency: Agency for International Development Category: Health Funding Amount: $35,500,000 |
| Postdoctoral Research Associate Training (PRAT) Program (Fi2) Apply for PAR 19 286 Funding Number: PAR 19 286 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Drug Screening with Biofabricated 3-D Skin Disease Tissue Models (U18 Clinical Trial Not Allowed) Apply for RFA TR 19 020 Funding Number: RFA TR 19 020 Agency: National Institutes of Health Category: Health Funding Amount: $400,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AT 19 011", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.